542
Participants
Start Date
September 30, 2013
Primary Completion Date
July 6, 2018
Study Completion Date
July 6, 2018
Afatinib
Patient will receive afatinib once daily
Chang-Gung Memorial Hospital, Linkou, Taoyuan
NCKUH, Tainan City
E-Da Hospital, Kaohsiung City
Tri-Service General Hospital, Taipei
307 Hospital of PLA, Beijing
Beijing Cancer Hospital, Beijing
Chinese PLA General Hospital, Beijing
Max Super Speciality Hospital, Delhi, Delhi
National Cancer Centre, Singapore
Shanghai Chest Hospital, Shanghai
Fudan University Shanghai Cancer Center, Shanghai
Shanghai Pulmonary Hospital, Shanghai
Jiangsu Cancer Hospital, Nanjing
Lin Yi Tumor Hospital, Linyi
Tianjin Medical University Cancer Institute and Hospital, Tianjin
SEAROC Cancer Centre, Jaipur
Zhejiang Cancer Hospital, Hangzhou
Prince Aly Khan Hospital, Mumbai
Ruby Hall Clinic, Pune
Shatabdi Superspeciality Hospital, Maharashtra
Global Hospitals, Hyderabad
Basavatarakam Indo - American Cancer Hospital & Research Ins, Hyderabad
Guangdong Provincial People's Hospital, Guangzhou
HCG Hospital, Bengaluru
Vikram Hospital, Bangalore
V S Hospital, Chennai
P VS Hospital Pvt Ltd, Calicut
B. P. Poddar Hospital & Medial Research Ltd, Kolkata,West Bengal
Jilin Province Cancer Hospital, Changchun
Queen Mary Hospital, Hong Kong
Prince of Wales Hospital, Shatin
Asirvatham Multispeciality Hospital, Madurai
Curie Manavata Cancer Centre, Maharashtra
Lead Sponsor
Boehringer Ingelheim
INDUSTRY